Who Owns Oramed Pharmaceuticals Stock?
NASDAQ: ORMPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 45.14%
- Held by insiders
- 21.27%
- Institutional holders
- 119
- Institutions 45.1%
- Insiders 21.3%
- Public and other 33.6%
Who owns Oramed Pharmaceuticals stock?
Institutional investors own about 45.1% of Oramed Pharmaceuticals's shares, spread across 119 institutions that file 13F reports. That level of institutional ownership is moderate. Insiders, including executives, directors and large founding shareholders, hold 21.27% of ORMP.
The largest institutional holders are Mercer Global Advisors, Inc./ADV (9.16%), Aquamarine Financial (cayman) Ltd (6.04%) and Gem Investment Advisors, LLC (4.81%). Together, the top 10 institutions control 32.8% of shares outstanding. In their latest filings, 7 of the top 10 institutions increased their ORMP positions and 3 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of ORMP
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Mercer Global Advisors, Inc./ADV | 3.81M | 9.16% | +99.5% |
| Aquamarine Financial (cayman) Ltd | 2.51M | 6.04% | +18.9% |
| Gem Investment Advisors, LLC | 2.00M | 4.81% | +21.9% |
| Blackrock Inc. | 1.61M | 3.87% | +1644.3% |
| Murchinson Ltd. | 1.29M | 3.10% | -1.9% |
| BML Capital Management, LLC | 866.27K | 2.08% | -72.7% |
| Boothbay Fund Management, LLC | 578.64K | 1.39% | -3.7% |
| Geode Capital Management, LLC | 500.69K | 1.20% | +1962.0% |
| Goldman Sachs Group Inc | 253.29K | 0.61% | +100.0% |
| State Street Corporation | 242.10K | 0.58% | +100.0% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of ORMP
| Fund | Shares | % Held |
|---|---|---|
| iShares Trust-iShares Russell 2000 ETF | 625.04K | 1.50% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 378.48K | 0.91% |
| iShares Trust-iShares Russell 2000 Value ETF | 315.20K | 0.76% |
| iShares Trust-iShares Micro-Cap ETF | 117.33K | 0.28% |
| SCHWAB CAPITAL TRUST-Schwab Small-Cap Index Fund | 83.63K | 0.20% |
| Quantitative Master Series LLC-Master Small Cap Index Series | 63.62K | 0.15% |
| Goldman Sachs ETF TRT-Goldman Sachs ActiveBeta(R) U.S. Small Cap Eqy. | 58.03K | 0.14% |
| American Century ETF Trust-Avantis U.S. Small Cap Equity ETF | 55.62K | 0.13% |
| Fidelity Salem Street Trust-Fidelity Small Cap Value Index Fund | 50.36K | 0.12% |
| TIAA-CREF Funds-Nuveen Small Cap Blend Index Fund | 46.40K | 0.11% |
Frequently asked questions
Who is the largest shareholder of Oramed Pharmaceuticals?
Mercer Global Advisors, Inc./ADV is the largest institutional shareholder of ORMP, owning 9.16% of shares outstanding (3.81M shares) as of its latest 13F filing.
What percentage of Oramed Pharmaceuticals is owned by institutions?
Institutions own about 45.1% of ORMP shares and 57.3% of the public float.
How much of Oramed Pharmaceuticals do insiders own?
Insiders, such as officers and directors, own about 21.27% of ORMP shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.